Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 3, 2010, Pages 1283-1289

  Niesters, H G M ^a,i   Zoulim, F ^b,c,d   Pichoud, C ^b,c,d   Buti, M ^e,f   Shapiro, F ^g   D'Heuvaert, N ^g   Celis, L ^g   Doutreloigne, J ^h   Sablon, E ^h  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b INSERM   (France)

^c UNIVERSITÉ LYON 1   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f INSTITUTO DE SALUD CARLOS III   (Spain)

^g Clinical Development and Medical Affairs Department   (Belgium)

^h Hepatology Unit   (Belgium)

ⁱ UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; EMTRICITABINE; FAMCICLOVIR; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; TELBIVUDINE;

ARTICLE; ASSAY; BLOOD SAMPLING; CODON; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GENE AMPLIFICATION; GENE MUTATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MIXED INFECTION; MUTANT; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; POPULATION; PRIORITY JOURNAL; VALIDATION STUDY; VIROTHERAPY; WILD TYPE;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG MONITORING; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; NUCLEIC ACID HYBRIDIZATION; NUCLEOSIDES; REAGENT KITS, DIAGNOSTIC; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

EID: 77149126703     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00970-09     Document Type: Article

References (25)

1. Aberle, S. W., J. Kletzmayr, B. Watschinger, B. Schmied, N. Vetter, and E. Puchhammer-Stockl. 2001. Comparison of sequence analysis and the INNOLiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions. J. Clin. Microbiol. 39:1972-1974.
2. Brunelle, M. N., A. C. Jacquard, C. Pichoud, D. Durantel, S. Carrouee-Durantel, J. P. Villeneuve, C. Trepo, and F. Zoulim. 2005. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir. Hepatology 41:1391-1398.
3. Degertekin, B., M. Hussain, J. Tan, K. Oberhelman, and A. S. Lok. 2009. Sensitivity and accuracy of an updated line probe assay (HBV DR v. 3) in detecting mutations associated with hepatitis B antiviral resistance. J. Hepatol. 50:42-48.
4. Dienstag, J. L., E. R. Schiff, T. L. Wright, R. P. Perrillo, H. W. Hann, Z. Goodman, et al. 1999. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 341:1256-1263.
5. Hadziyannis, S. J., G. V. Papatheodoridis, E. Dimou, A. Laras, and C. Papaioannou. 2000. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 32(Pt. 1):847-851.
6. Hadziyannis, S. J., N. C. Tassopoulos, E. J. Heathcote, T. T. Chang, G. Kitis, M. Rizzetto, P. Marcellin, S. G. Lim, Z. Goodman, J. Ma, C. L. Brosgart, K. Borroto-Esoda, S. Arterburn, S. L. Chuck, and the Adefovir Dipivoxil 438 Study Group. 2006. Long-term therapy with adefovir dipivoxil for HBeAgnegative chronic hepatitis B for up to 5 years. Gastroenterology 131:1743-1751.
7. Honkoop, P., R. A. de Man, H. G. Niesters, P. E. Zondervan, and S. W. Schalm. 2000. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 32:635-639.
8. Hussain, M., S. Fung, E. Libbrecht, E. Sablon, C. Cursaro, P. Andreone, et al. 2006. Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir. J. Clin. Microbiol. 44:1094-1097.
9. Lai, C. L., R. N. Chien, N. W. Leung, T. T. Chang, R. Guan, D. I. Tai, et al., for the Asia Hepatitis Lamivudine Study Group. 1998. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 339:61-68.
10. Lai, C. L., J. Dienstag, E. Schiff, N. W. Leung, M. Atkins, C. Hunt, et al. 2003. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin. Infect. Dis. 36:687-696.
11. Lai, C. L., N. Leung, E. K. Teo, M. Tong, F. Wong, H. W. Hann, et al. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
12. Lampertico, P., M. Vigano, E. Manenti, M. Iavarone, G. Lunghi, and M. Colombo. 2005. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 42:1414-1419.
13. Leung, N. W., C. L. Lai, T. T. Chang, R. Guan, C. M. Lee, K. Y. Ng, et al., on behalf of the Asia Hepatitis Lamivudine Study Group. 2001. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 33:1527-1532.
14. Liaw, Y. F., R. N. Chien, C. T. Yeh, S. L. Tsai, and C. M. Chu. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
15. Lim, S. G., T. M. Ng, N. Kung, Z. Krastev, M. Volfova, P. Husa, et al. 2006. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med. 166:49-56.
16. Lok, A. S., F. Zoulim, S. Locarnini, A. Mangia, G. Niro, H. Decraemer, G. Maertens, F. Hulstaert, K. De Vreese, and E. Sablon. 2002. Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay. J. Clin. Microbiol. 40:3729-3734.
17. Nafa, S., S. Ahmed, D. Tavan, C. Pichoud, F. Berby, L. Stuyver, et al. 2000. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 32:1078-1088.
18. Osiowy, C., J. P. Villeneuve, E. J. Heathcote, E. Giles, and J. Borlang. 2006. Detection of rtN236T and rtA181V/T mutations associated with resistance to adefovir dipivoxil in samples from patients with chronic hepatitis B virus infection by the INNO-LiPA HBV DR line probe assay (version 2). J. Clin. Microbiol. 44:1994-1997.
19. Sablon, E., and F. Shapiro. 2005. Advances in molecular diagnosis of HBV infection and drug resistance. Int. J. Med. Sci. 2:8-16.
20. Southern, E., K. Mir, and M. Shchepinov. 1999. Molecular interaction on microarrays. Nat. Genet. 21(Suppl.):5-9.
21. Tillmann, H. L. 2007. Antiviral therapy and resistance with hepatitis B virus infection. World J. Gastroenterol. 13:125-140.
22. Villet, S., A. Ollivet, C. Pichoud, L. Barraud, J. P. Villeneuve, C. Trepo, and F. Zoulim. 2007. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J. Hepatol. 46:531-538.
23. Villet, S., C. Pichoud, J. P. Villeneuve, C. Trepo, and F. Zoulim. 2006. Selection of a multiple drug-resistant hepatitis B virus strain in a livertransplanted patient. Gastroenterology 131:1253-1261.
24. Yang, H., X. Qi, A. Sabogal, M. Miller, S. Xiong, and W. E. Delaney IV. 2005. Cross-resistance testing of next-generation nucleoside and nucleotide analogues against lamivudine-resistant HBV. Antivir. Ther. 10:625-633.
25. Yim, H. J., M. Hussain, Y. Liu, S. N. Wong, S. K. Fung, and A. S. Lok. 2006. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44:703-712.